Scinai Immunotherapeutics (SCNI) Gains from Sales and Divestitures (2022 - 2025)

Scinai Immunotherapeutics has disclosed Gains from Sales and Divestitures across 4 years of filings, most recently posting $26974.0 for Q4 2025.

• Gains from Sales and Divestitures for Q4 2025 came in at $26974.0, up 69.72% year-over-year; the trailing twelve-month figure through Dec 2025 was $26974.0 (up 69.72% YoY), and the FY2025 annual result was $26974.0, up 69.72% from the prior year.
• Gains from Sales and Divestitures came in at $26974.0 for Q4 2025 at Scinai Immunotherapeutics, up from $15893.0 in the prior quarter.
• In the past five years, Gains from Sales and Divestitures ranged from a high of $26974.0 in Q4 2025 to a low of $278.0 in Q4 2022.
• The 4-year median for Gains from Sales and Divestitures is $8751.0 (2023), against an average of $11188.5.
• Across the five-year window, Gains from Sales and Divestitures surged 887.76% in 2024 and surged 69.72% in 2025, its largest moves.
• Scinai Immunotherapeutics' Gains from Sales and Divestitures stood at $278.0 in 2022, then surged by 478.78% to $1609.0 in 2023, then soared by 887.76% to $15893.0 in 2024, then soared by 69.72% to $26974.0 in 2025.
• The last three Gains from Sales and Divestitures figures came in at $26974.0 (Q4 2025), $15893.0 (Q4 2024), and $1609.0 (Q4 2023), per Business Quant data.